Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha

Blood. 2001 Jun 1;97(11):3648-50. doi: 10.1182/blood.v97.11.3648.

Abstract

Recently, it was shown that interferon consensus sequence binding protein (ICSBP), a member of the interferon regulatory factor (IRF) family, has a potential role in chronic myeloid leukemia (CML). Deletion of ICSBP gene in mice leads to a CML-like syndrome and samples from CML patients exhibited impaired ICSBP expression. The present study found that ICSBP expression correlated with risk features determined by Sokal score in untreated CML (P =.007 for high versus low risk). In addition, analyzing ICSBP expression during interferon-alpha (IFN-alpha) therapy in "good" (n = 27) versus "poor" (n = 15) cytogenetic responders, high ICSBP levels were only observed in "good" responders (P =.0002). Together, these data suggest that ICSBP levels are related to initial presentation of CML and the therapeutic response of CML to IFN-alpha, indicating an important role of ICSBP in CML. (Blood. 2001;97:3648-3650)

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cytogenetic Analysis
  • Gene Expression*
  • Humans
  • Interferon Regulatory Factors
  • Interferon-alpha / therapeutic use*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • RNA, Messenger / blood
  • Repressor Proteins / blood
  • Repressor Proteins / genetics*
  • Repressor Proteins / physiology
  • Retrospective Studies
  • Risk Factors

Substances

  • Interferon Regulatory Factors
  • Interferon-alpha
  • RNA, Messenger
  • Repressor Proteins
  • interferon regulatory factor-8